Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04950959 · ClinicalTrials.gov registry record
XACT ACE Observational Registry
A clinical trial of Tumors, sponsored by Xact Robotics.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT04950959 is a study of Tumors that is actively recruiting participants, run by Xact Robotics. The registered enrollment target is 500 participants, above the 174-participant average among 20 other Tumors trials with a reported enrollment target (187% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04950959, a study of Tumors, is actively recruiting participants, sponsored by Xact Robotics.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Compile real world data on the use of the XACT ACE Robotic System
Conditions Studied
Interventions
- DEVICE Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T
Study Locations (1)
Massachusetts
- Lahey Hospital and Medical Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2026-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04950959
The ClinicalTrials.gov registry entry for NCT04950959 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 174-participant average among 20 other Tumors trials with a reported enrollment target (187% higher). The listed sponsor is Xact Robotics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T is the first listed.
NCT04950959 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04950959 about?
NCT04950959 is a clinical study titled "XACT ACE Observational Registry". Compile real world data on the use of the XACT ACE Robotic System
What is the current status of trial NCT04950959?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2021-10-01. Estimated completion is 2026-08-01.
What conditions does trial NCT04950959 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT04950959?
The interventions under investigation include: Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T (DEVICE).
Who is sponsoring clinical trial NCT04950959?
This trial is sponsored by Xact Robotics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04950959 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors
RECRUITING
-
Perioperative Risk Study
ACTIVE NOT RECRUITING · NA
-
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
ACTIVE NOT RECRUITING · Phase 2
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.